Pulmonx (LUNG) Free Cash Flow Growth (1y) (2020 - 2025)
Pulmonx (LUNG) Free Cash Flow Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -14.34% |
| 10 | Pulmonx | 93.95 Mn | 24.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -8.23% |
| Jun 30, 2025 | 37.82% |
| Mar 31, 2025 | -10.94% |
| Dec 31, 2024 | 20.55% |
| Sep 30, 2024 | 13.59% |
| Jun 30, 2024 | 20.36% |
| Mar 31, 2024 | 6.57% |
| Dec 31, 2023 | 13.69% |
| Sep 30, 2023 | 19.65% |
| Jun 30, 2023 | 20.27% |
| Mar 31, 2023 | 15.89% |
| Dec 31, 2022 | 15.80% |
| Sep 30, 2022 | -10.68% |
| Jun 30, 2022 | 26.11% |
| Mar 31, 2022 | -56.81% |
| Dec 31, 2021 | -50.81% |
| Sep 30, 2021 | -56.71% |
| Jun 30, 2021 | -72.67% |
| Mar 31, 2021 | -3.35% |
| Dec 31, 2020 | -111.13% |